Actuate Therapeutics, Inc. Statistics
Actuate Therapeutics, Inc. (ACTU) Stock Statistics & Valuation Metrics
Total Valuation
Actuate Therapeutics, Inc. has a market cap or net worth of $16.18M. The enterprise value is $41.32T.
- Market Cap
- $16.18M
- Enterprise Value
- $41.32T
Share Statistics
Actuate Therapeutics, Inc. has 60,382,824 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 60,382,824
- Owned by Insiders
- 24.77%
- Owned by Institutions
- 24.41%
Financial Efficiency
Actuate Therapeutics, Inc.’s return on equity (ROE) is -2.81 and return on invested capital (ROIC) is -270.08%.
- Return on Equity (ROE)
- -2.81
- Return on Assets (ROA)
- -1.58
- Return on Invested Capital (ROIC)
- -270.08%
- Return on Capital Employed (ROCE)
- -2.70
- Revenue Per Employee
- 0
- Profits Per Employee
- -1.85M
- Employee Count
- 12
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Actuate Therapeutics, Inc. is -0.35. Actuate Therapeutics, Inc.’s PEG ratio is -0.01.
- PE Ratio
- -0.35
- PS Ratio
- 0.00
- PB Ratio
- -8.19
- Price to FCF
- -0.41
- Price to Operating Cash Flow
- -0.41
- PEG Ratio
- -0.01
Income Statement
In the last 12 months, Actuate Therapeutics, Inc. had revenue of 0 and earned -22.23M in profits. Earnings per share was -1.06.
- Revenue
- 0
- Gross Profit
- 0
- Operating Income
- -22.50M
- Pretax Income
- -22.23M
- Net Income
- -22.23M
- EBITDA
- -22.21M
- Earnings Per Share (EPS)
- -1.06
Cash Flow
In the last 12 months, operating cash flow was -16.11M and capital expenditures -4, giving a free cash flow of -16.11M billion.
- Operating Cash Flow
- -16.11M
- Free Cash Flow
- -16.11M
- Free Cash Flow per Share
- -0.67
Dividends & Yields
Actuate Therapeutics, Inc. pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -242.17%
- Earnings Yield
- -275.23%
Stock Price Statistics
- Beta
- 1.31
- 52-Week Price Change
- -95.47%
- 50-Day Moving Average
- 0.67
- 200-Day Moving Average
- 1.86
- Relative Strength Index (RSI)
- 28.75
- Average Volume (3m)
- 427.40K
Financial Position
Actuate Therapeutics, Inc. as a current ratio of 2.39, with Debt / Equity ratio of 5.11%
- Current Ratio
- 2.39
- Quick Ratio
- 2.39
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 0.57
- Interest Coverage Ratio
- -1110.88
Taxes
In the past 12 months, Actuate Therapeutics, Inc. has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
Actuate Therapeutics, Inc. EV to EBITDA ratio is -0.27, with an EV/FCF ratio of -0.31.
- EV to Sales
- 0.00
- EV to EBITDA
- -0.27
- EV to Free Cash Flow
- -0.31
- EV to Operating Cash Flow
- -0.31
Balance Sheet
Actuate Therapeutics, Inc. has $2.10M in cash and marketable securities with $404.99K in debt, giving a net cash position of $1.70M billion.
- Cash & Marketable Securities
- $2.10M
- Total Debt
- $404.99K
- Net Cash
- $1.70M
- Net Cash Per Share
- $0.03
- Tangible Book Value Per Share
- -$0.03
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Pretax Margin
- 0.00%
- Net Profit Margin
- 0.00%
- EBITDA Margin
- 0.00%
- EBIT Margin
- 0.00%
Analyst Forecast
The average price target for Actuate Therapeutics, Inc. is $10.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
- Price Target
- $10.00
- Price Target Upside
- 3631.34% Upside
- Analyst Consensus
- Moderate Buy
- Analyst Count
- 1
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- 35.52%

